Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Bachelot, Thomas; Filleron, Thomas; Bièche, Ivan; Arnedos, Mónica; Campone, Mario; Dalenc, Florence; Coussy, Florence; Sablin, Marie‐Paule; Debled, Marc; Lefeuvre-Plesse, Claudia; Gonçalvès, Anthony; Mouret-Reynier, Marie-Ange; Jacot, William; You, Benoît; Barthélémy, Philippe; Isambert, Nicolás; Tchiknavorian, X.; Lévy, Christelle; Théry, Jean-Christophe; L’Haridon, Tifenn; Ferrero, Jean-­Marc; Mège, Alice; Piano, Francesco Del; Rouleau, Étienne; Tran-Dien, Alicia; Adam, Julien; Lusque, Amélie; Jimenez, Marta; Jacquet, Alexandra; Garberis, Ingrid; Varga, Andrea

doi:10.1038/s41591-020-01189-2

Cited by 111 publications

(99 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…That is, neoadjuvant chemotherapy including taxanes has better therapeutic effect and easier access to neoadjuvant chemotherapy pCR. The literature [4] randomized 316 patients receiving neoadjuvant chemotherapy into the CEF or DE (docetaxel 75 mg/m 2 , epirubicin 60 mg/m 2) chemotherapy regimen group. The study found that the overall response rate of the DE group is better than that of the FEC group in patients with early tumors (stage I-IIa).…”

Section: Related Workmentioning

confidence: 99%

Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer

Jiang

Liu

Gai

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

With the continuous development of the concept of diagnosis and treatment, the current industry’s treatment model has developed into a multidisciplinary comprehensive treatment. That is, in view of the pathological characteristics and clinical stages of breast cancer, corresponding methods such as surgery, chemotherapy, endocrine therapy, radiotherapy, and biological targeted therapy are adopted to provide comprehensive treatment of patients with multiple disciplines. This paper combines experimental research to research and analyze the degree of pathological remission of breast cancer by adjuvant chemotherapy and combines investigation and analysis and group trials to study and explore the effect of adjuvant chemotherapy. Moreover, this paper fully considers the patient’s response to neoadjuvant chemotherapy and compares the changes in tumor cell abundance before and after chemotherapy to observe the response of the patient’s primary tumor to chemotherapy at a microscopic level. Therefore, this study has made a relatively objective and accurate evaluation of the chemotherapy efficacy of tumor tissues, which can provide a reference for subsequent related research.

show abstract

Section: Related Workmentioning

confidence: 99%

Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer

Jiang

Liu

Gai

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…This combination increased pCR rate, particularly in patients pretreated with durvalumab monotherapy before chemotherapy. Another randomized phase II study, SAFIRO BREAST-IMMUNO, compared durvalumab to maintenance chemotherapy in a cohort including TNBC patients [ 324 ]. Results showed that durvalumab, as a single agent therapy, could improve outcomes in TNBC patients.…”

Section: New Strategies and Challenges For Breast Cancer Treatmentmentioning

confidence: 99%

Breast Cancer Treatments: Updates and New Challenges

Burguin

Diorio

Durocher

2021

JPM

210

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B, HER2 and triple-negative breast cancer (TNBC)) according to the expression of the estrogen receptor (ER) and the progesterone receptor (PR), and the overexpression of the human epidermal growth factor receptor 2 (HER2). Current BC treatments target these receptors (endocrine and anti-HER2 therapies) as a personalized treatment. Along with chemotherapy and radiotherapy, these therapies can have severe adverse effects and patients can develop resistance to these agents. Moreover, TNBC do not have standardized treatments. Hence, a deeper understanding of the development of new treatments that are more specific and effective in treating each BC subgroup is key. New approaches have recently emerged such as immunotherapy, conjugated antibodies, and targeting other metabolic pathways. This review summarizes current BC treatments and explores the new treatment strategies from a personalized therapy perspective and the resulting challenges.

show abstract

“…The Dako PD-L1 IHC 22C3 pharmDx assay defined PD-L1 positivity as a combined positive score of ≥1, while in the Ventana PD-L1 IHC SP142 assay, positivity was defined as ≥1 % expression in tumor-infiltrating immune cells (Figure 5) (Table A1). The different assays have been specifically implemented in relation to the clinical evidence from trials and validated with specific platforms [177][178][179]. Regardless, in addition to specific companion diagnostics, 22C3 (Dako) and SP263 (Ventana) are antibody clones generally accepted by pharmaceuticals for clinical use.…”

Section: Programmed Cell Death-ligandmentioning

confidence: 99%

Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment

Tsang

Tse

2021

Cancers

108

View full text Add to dashboard Cite

The tumor microenvironment (TME) in breast cancer comprises local factors, cancer cells, immune cells and stromal cells of the local and distant tissues. The interaction between cancer cells and their microenvironment plays important roles in tumor proliferation, propagation and response to therapies. There is increasing research in exploring and manipulating the non-cancerous components of the TME for breast cancer treatment. As the TME is now increasingly recognized as a treatment target, its pathologic assessment has become a critical component of breast cancer management. The latest WHO classification of tumors of the breast listed stromal response pattern/fibrotic focus as a prognostic factor and includes recommendations on the assessment of tumor infiltrating lymphocytes and PD-1/PD-L1 expression, with therapeutic implications. This review dissects the TME of breast cancer, describes pathologic assessment relevant for prognostication and treatment decision, and details therapeutic options that interacts with and/or exploits the TME in breast cancer.

show abstract

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Cited by 111 publications

References 31 publications

Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer

Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer

Breast Cancer Treatments: Updates and New Challenges

Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment

Contact Info

Product

Resources

About